Showing 1451-1460 of 3308 results for "".
Currents: Cosmetic Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/currents-cosmetic-dermatology/23463/GLP-1RAs and the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1ras-and-the-dermatologist/48885/We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation.Of Pandemics and Postponements
https://practicaldermatology.com/topics/practice-management/of-pandemics-and-postponements/23342/Music City SCALE Wrap-Up
https://practicaldermatology.com/conferences/scale-2024/music-city-scale-wrap/26555/Music City SCALE Wrap-UpBlinded by the Light—and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/blinded-by-the-lightand-more/23154/CSF faculty members share their favorite Energy- and Light-Based Devices.New in My Practice: OTC/New Products
https://practicaldermatology.com/columns/new-products/new-in-my-practice-otcnew-products-2/23654/Sneak Peek: CSF Returns to Nashville
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2021/sneak-peek-csf-returns-to-nashville/23617/Next month’s live meeting covers a range of hot topics in dermatology.CSF Faculty: Sunscreen Picks
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2021/csf-faculty-sunscreen-picks/23490/Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P